Global Gene Therapy Market – Analysis By Vector Type, By Application, By Region, By Country (2020 Edition): Market Insights, Covid-19 Impact, Competition And Forecast (2020-2025)

Table of Contents

1. Research Methodology and Executive Summary
1.1 Research Methodology
1.2 Executive Summary

2. Strategic Recommendations

3. Gene Therapy Market: Product Outlook

4. Global Gene Therapy Market: Sizing and Forecast
4.1 Market Size, By Value, Year 2015-2025

5. Global Gene Therapy Market Segmentation – By Vector Type, and By Application
5.1 Competitive Scenario of Global Gene Therapy Market: By Vector Type
5.1.1 Lentivirus – Market Size and Forecast (2015-2025)
5.1.2 AAV – Market Size and Forecast (2015-2025)
5.1.3 Retrovirus & Gammaretrovirus – Market Size and Forecast (2015-2025)
5.1.4 Others – Market Size and Forecast (2015-2025)
5.2 Competitive Scenario of Global Gene Therapy Market: By Application
5.2.1 Neurological Disorders – Market Size and Forecast (2015-2025)
5.2.2 Cancer – Market Size and Forecast (2015-2025)
5.2.3 Cardiovascular Diseases – Market Size and Forecast (2015-2025)
5.2.4 Others – Market Size and Forecast (2015-2025)

6. Global Gene Therapy Market: Regional Analysis
6.1 Competitive Scenario of Global Gene Therapy Market: By Region

7. North America Gene Therapy Market: An Analysis (2015-2025)
7.1 North America Gene Therapy Market: Size and Forecast (2015-2025), By Value
7.2 North America Gene Therapy Market – Prominent Companies
7.3 Market Segmentation By Vector Type (Lentivirus, AAV, Retrovirus & Gammaretrovirus and Others)
7.4 Market Segmentation By Application (Neurological Disorders, Cancer, Cardiovascular Diseases and Others)

7.5 North America Gene Therapy Market: Country Analysis
7.6 Market Opportunity Chart of North America Gene Therapy Market - By Country, By Value, 2025
7.7 Competitive Scenario of North America Gene Therapy Market : By Country
7.8 United States Gene Therapy Market: Size and Forecast (2015-2025), By Value
7.9 United States Gene Therapy Market Segmentation - By Vector Type, and By Application (2015-2025)
7.10 Canada Gene Therapy Market: Size and Forecast (2015-2025), By Value
7.11 Canada Gene Therapy Market Segmentation - By Vector Type, and By Application (2015-2025)

8. Europe Gene Therapy Market: An Analysis (2015-2025)
8.1 Europe Gene Therapy Market: Size and Forecast (2015-2025), By Value
8.2 Europe Gene Therapy Market – Prominent Companies
8.3 Market Segmentation By Vector Type (Lentivirus, AAV, Retrovirus & Gammaretrovirus and Others)
8.4 Market Segmentation By Application (Neurological Disorders, Cancer, Cardiovascular Diseases and Others)

8.5 Europe Gene Therapy Market: Country Analysis
8.6 Market Opportunity Chart of Europe Gene Therapy Market - By Country, By Value, 2025
8.7 Competitive Scenario of Europe Gene Therapy Market : By Country
8.8 Germany Gene Therapy Market: Size and Forecast (2015-2025), By Value
8.9 Germany Gene Therapy Market Segmentation - By Vector Type, and By Application (2015-2025)
8.10 France Gene Therapy Market: Size and Forecast (2015-2025), By Value
8.11 France Gene Therapy Market Segmentation - By Vector Type, and By Application (2015-2025)
8.12 United Kingdom Gene Therapy Market: Size and Forecast (2015-2025), By Value
8.13 United Kingdom Gene Therapy Market Segmentation - By Vector Type, and By Application (2015-2025)
8.14 Italy Gene Therapy Market: Size and Forecast (2015-2025), By Value
8.15 Italy Gene Therapy Market Segmentation - By Vector Type, and By Application (2015-2025)

9. Asia Pacific Gene Therapy Market: An Analysis (2015-2025)
9.1 Asia Pacific Gene Therapy Market: Size and Forecast (2015-2025), By Value
9.2 Asia Pacific Gene Therapy Market – Prominent Companies
9.3 Market Segmentation By Vector Type (Lentivirus, AAV, Retrovirus & Gammaretrovirus and Others)
9.4 Market Segmentation By Application (Neurological Disorders, Cancer, Cardiovascular Diseases and Others)

9.5 Asia Pacific Gene Therapy Market: Country Analysis
9.6 Market Opportunity Chart of Asia Pacific Gene Therapy Market - By Country, By Value, 2025
9.7 Competitive Scenario of Asia Pacific Gene Therapy Market : By Country
9.8 China Gene Therapy Market: Size and Forecast (2015-2025), By Value
9.9 China Gene Therapy Market Segmentation - By Vector Type, and By Application (2015-2025)
9.10 Japan Gene Therapy Market: Size and Forecast (2015-2025), By Value
9.11 Japan Gene Therapy Market Segmentation - By Vector Type, and By Application (2015-2025)
9.12 India Gene Therapy Market: Size and Forecast (2015-2025), By Value
9.13 India Gene Therapy Market Segmentation - By Vector Type, and By Application (2015-2025)
9.14 South Korea Gene Therapy Market: Size and Forecast (2015-2025), By Value
9.15 South Korea Gene Therapy Market Segmentation - By Vector Type, and By Application (2015-2025)

10. Global Gene Therapy Market Dynamics
10.1 Drivers
10.2 Restraints
10.3 Trends

11. Market Attractiveness
11.1 Market Attractiveness Chart of Global Gene Therapy Market - By Vector Type, 2025
11.2 Market Attractiveness Chart of Global Gene Therapy Market - By Application, 2025
11.3 Market Attractiveness Chart of Global Gene Therapy Market - By Region, 2025

12. Competitive Landscape
12.1 Major Technological Innovations, Mergers & Acquisitions and Role of Manufacturers During COVID–19
12.2 Product Pipeline of Leading Gene Therapy Companies
12.3 Market Share Analysis

13. Company Analysis (Business Description, Financial Analysis, Business Strategy)
13.1 Voyager Therapeutics
13.2 Novartis AG
13.3 Spark Therapeutics Inc.
13.4 MoldMed S.P.A.
13.5 Orchard Therapeutics PLC
13.6 Alnylam Pharmaceuticals Inc.
13.7 AnGes Inc.
13.8 Akcea Therapeutics
13.9 BlueBird Bio Inc.
13.10 Sarepta Therapeutics

List of Figures

Figure 1: Global Gene Therapy Market Size, By Value, 2015-2025 (USD Million)
Figure 2: Global Prevalence of Neurological Disorders, 2015-2019 (In Billions)
Figure 3: Global Prevalence of Cardiovascular Diseases, 2015-2019 (In Millions)
Figure 4: Global Prevalence of Total Cancer, 2015-2019 (In Millions)
Figure 5: Global Prevalence of Schizophrenia, 2015-2019 (In Millions)
Figure 6: Global Prevalence of Alzheimer's Disease and Other Dementias, 2015-2019 (In Millions)
Figure 7: Global Prevalence of Sickle Cell Disorders, 2015-2019 (In Millions)
Figure 8: Global Prevalence of Mesothelioma, 2015-2019 (In Thousands)
Figure 9: Global Gene Therapy Market, By Vector Type, 2019, 2025
Figure 10: Global Gene Therapy Market - By Lentivirus, By Value (USD Million), 2015-2025
Figure 11: Global Gene Therapy Market - By AAV, By Value (USD Million), 2015-2025
Figure 12: Global Gene Therapy Market - By Retrovirus and Gammaretrovirus, By Value (USD Million), 2015-2025
Figure 13: Global Gene Therapy Market – By Others, By Value (USD Million), 2015-2025
Figure 14: Global Gene Therapy Market, By Application, 2019, 2025
Figure 15: Global Gene Therapy Market - By Neurological Disorders, By Value (USD Million), 2015-2025
Figure 16: Global Gene Therapy Market - By Cancer, By Value (USD Million), 2015-2025
Figure 17: Global Gene Therapy Market - By Cardiovascular Disorders, By Value (USD Million), 2015-2025
Figure 18: Global Gene Therapy Market - By Others, By Value (USD Million), 2015-2025
Figure 19: Global Gene Therapy Market, By Region, 2019, 2025
Figure 20: North America Gene Therapy Market Size, By Value, 2015-2025 (USD Million)
Figure 21: North America Prevalence of Neurological Disorders, 2015-2019 (In Billions)
Figure 22: North America Prevalence of Cardiovascular Diseases, 2015-2019 (In Millions)
Figure 23: North America Prevalence of Total Cancer, 2015-2019 (In Millions)
Figure 24: North America Prevalence of Schizophrenia, 2015-2019 (In Millions)
Figure 25: North America Prevalence of Alzheimer's Disease and Other Dementias, 2015-2019 (In Millions)
Figure 26: North America Prevalence of Sickle Cell Disorders, 2015-2019 (In Millions)
Figure 27: North America Prevalence of Mesothelioma, 2015-2019 (In Thousands)
Figure 28: North America Gene Therapy Market - By Vector Type, By Value, 2015-2025 (USD Million)
Figure 29: North America Gene Therapy Market - By Application, By Value, 2015-2025 (USD Million)
Figure 30: Market Opportunity Chart of North America Gene Therapy Market - By Country, By Value, 2025
Figure 31: North America Gene Therapy Market, By Country, 2019, 2025
Figure 32: United States Gene Therapy Market Size, By Value, 2015-2025 (USD Million)
Figure 33: United States Prevalence of Neurological Disorders, 2015-2019 (In Billions)
Figure 34: United States Prevalence of Cardiovascular Diseases, 2015-2019 (In Millions)
Figure 35: United States Prevalence of Total Cancer, 2015-2019 (In Millions)
Figure 36: United States Prevalence of Schizophrenia, 2015-2019 (In Millions)
Figure 37: United States Prevalence of Alzheimer's Disease and Other Dementias, 2015-2019 (In Millions)
Figure 38: United States Prevalence of Sickle Cell Disorders, 2015-2019 (In Millions)
Figure 39: United States Prevalence of Mesothelioma, 2015-2019 (In Thousands)
Figure 40: United States Average Income and Expenditures of All Consumer Units, 2017, 2018 (In %)
Figure 41: United States Gene Therapy Market - By Vector Type, By Value, 2015-2025 (USD Million)
Figure 42: United States Gene Therapy Market - By Application, By Value, 2015-2025 (USD Million)
Figure 43: Canada Gene Therapy Market Size, By Value, 2015-2025 (USD Million)
Figure 44: Canada Prevalence of Neurological Disorders, 2015-2019 (In Billions)
Figure 45: Canada Prevalence of Cardiovascular Diseases, 2015-2019 (In Millions)
Figure 46: Canada Prevalence of Total Cancer, 2015-2019 (In Millions)
Figure 47: Canada Prevalence of Schizophrenia, 2015-2019 (In Millions)
Figure 48: Canada Prevalence of Alzheimer's Disease and Other Dementias, 2015-2019 (In Millions)
Figure 49: Canada Prevalence of Sickle Cell Disorders, 2015-2019 (In Millions)
Figure 50: Canada Prevalence of Mesothelioma, 2015-2019 (In Thousands)
Figure 51: Canada Average Income and Expenditures of All Consumer Units, 2017, 2018 (In %)
Figure 52: Canada Gene Therapy Market - By Vector Type, By Value, 2015-2025 (USD Million)
Figure 53: Canada Gene Therapy Market - By Application, By Value, 2015-2025 (USD Million)
Figure 54: Europe Gene Therapy Market Size, By Value, 2015-2025 (USD Million)
Figure 55: Europe Prevalence of Neurological Disorders, 2015-2019 (In Billions)
Figure 56: Europe Prevalence of Cardiovascular Diseases, 2015-2019 (In Millions)
Figure 57: Europe Prevalence of Total Cancer, 2015-2019 (In Millions)
Figure 58: Europe Prevalence of Schizophrenia, 2015-2019 (In Millions)
Figure 59: Europe Prevalence of Alzheimer's Disease and Other Dementias, 2015-2019 (In Millions)
Figure 60: Europe Prevalence of Sickle Cell Disorders, 2015-2019 (In Millions)
Figure 61: Europe Prevalence of Mesothelioma, 2015-2019 (In Thousands)
Figure 62: European Union Household Expenditure, By Consumption Purpose, 2018 (In %)
Figure 63: Europe Gene Therapy Market - By Vector Type, By Value, 2015-2025 (USD Million)
Figure 64: Europe Gene Therapy Market - By Application, By Value, 2015-2025 (USD Million)
Figure 65: Market Opportunity Chart of Europe Gene Therapy Market - By Country, By Value, 2025
Figure 66: Europe Gene Therapy Market, By Country, 2019, 2025
Figure 67: Germany Gene Therapy Market Size, By Value, 2015-2025 (USD Million)
Figure 68: Germany Prevalence of Neurological Disorders, 2015-2019 (In Billions)
Figure 69: Germany Prevalence of Cardiovascular Diseases, 2015-2019 (In Millions)
Figure 70: Germany Prevalence of Total Cancer, 2015-2019 (In Millions)
Figure 71: Germany Prevalence of Schizophrenia, 2015-2019 (In Millions)
Figure 72: Germany Prevalence of Alzheimer's Disease and Other Dementias, 2015-2019 (In Millions)
Figure 73: Germany Prevalence of Sickle Cell Disorders, 2015-2019 (In Millions)
Figure 74: Germany Prevalence of Mesothelioma, 2015-2019 (In Thousands)
Figure 75: Germany Household Expenditure, By Consumption Purpose, 2018 (In %)
Figure 76: Germany Gene Therapy Market - By Vector Type, By Value, 2015-2025 (USD Million)
Figure 77: Germany Gene Therapy Market - By Application, By Value, 2015-2025 (USD Million)
Figure 78: France Gene Therapy Market Size, By Value, 2015-2025 (USD Million)
Figure 79: France Prevalence of Neurological Disorders, 2015-2019 (In Billions)
Figure 80: France Prevalence of Cardiovascular Diseases, 2015-2019 (In Millions)
Figure 81: France Prevalence of Total Cancer, 2015-2019 (In Millions)
Figure 82: France Prevalence of Schizophrenia, 2015-2019 (In Millions)
Figure 83: France Prevalence of Alzheimer's Disease and Other Dementias, 2015-2019 (In Millions)
Figure 84: France Prevalence of Sickle Cell Disorders, 2015-2019 (In Millions)
Figure 85: France Prevalence of Mesothelioma, 2015-2019 (In Thousands)
Figure 86: France Household Expenditure, By Consumption Purpose, 2018 (In %)
Figure 87: France Gene Therapy Market - By Vector Type, By Value, 2015-2025 (USD Million)
Figure 88: France Gene Therapy Market - By Application, By Value, 2015-2025 (USD Million)
Figure 89: United Kingdom Gene Therapy Market Size, By Value, 2015-2025 (USD Million)
Figure 90: United Kingdom Prevalence of Neurological Disorders, 2015-2019 (In Billions)
Figure 91: United Kingdom Prevalence of Cardiovascular Diseases, 2015-2019 (In Millions)
Figure 92: United Kingdom Prevalence of Total Cancer, 2015-2019 (In Millions)
Figure 93: United Kingdom Prevalence of Schizophrenia, 2015-2019 (In Millions)
Figure 94: United Kingdom Prevalence of Alzheimer's Disease and Other Dementias, 2015-2019 (In Millions)
Figure 95: United Kingdom Prevalence of Sickle Cell Disorders, 2015-2019 (In Millions)
Figure 96: United Kingdom Prevalence of Mesothelioma, 2015-2019 (In Thousands)
Figure 97: United Kingdom Household Expenditure, By Consumption Purpose, 2018 (In %)
Figure 98: United Kingdom Gene Therapy Market - By Vector Type, By Value, 2015-2025 (USD Million)
Figure 99: United Kingdom Gene Therapy Market - By Application, By Value, 2015-2025 (USD Million)
Figure 100: Italy Gene Therapy Market Size, By Value, 2015-2025 (USD Million)
Figure 101: Italy Prevalence of Neurological Disorders, 2015-2019 (In Billions)
Figure 102: Italy Prevalence of Cardiovascular Diseases, 2015-2019 (In Millions)
Figure 103: Italy Prevalence of Total Cancer, 2015-2019 (In Millions)
Figure 104: Italy Prevalence of Schizophrenia, 2015-2019 (In Millions)
Figure 105: Italy Prevalence of Alzheimer's Disease and Other Dementias, 2015-2019 (In Millions)
Figure 106: Italy Prevalence of Sickle Cell Disorders, 2015-2019 (In Millions)
Figure 107: Italy Prevalence of Mesothelioma, 2015-2019 (In Thousands)
Figure 108: Italy Household Expenditure, By Consumption Purpose, 2018 (In %)
Figure 109: Italy Gene Therapy Market - By Vector Type, By Value, 2015-2025 (USD Million)
Figure 110: Italy Gene Therapy Market - By Application, By Value, 2015-2025 (USD Million)
Figure 111: Asia Pacific Gene Therapy Market Size, By Value, 2015-2025 (USD Million)
Figure 112: Asia Pacific Prevalence of Neurological Disorders, 2015-2019 (In Billions)
Figure 113: Asia Pacific Prevalence of Cardiovascular Diseases, 2015-2019 (In Millions)
Figure 114: Asia Pacific Prevalence of Total Cancer, 2015-2019 (In Millions)
Figure 115: Asia Pacific Prevalence of Schizophrenia, 2015-2019 (In Millions)
Figure 116: Asia Pacific Prevalence of Alzheimer's Disease and Other Dementias, 2015-2019 (In Millions)
Figure 117: Asia Pacific Prevalence of Sickle Cell Disorders, 2015-2019 (In Millions)
Figure 118: Asia Pacific Prevalence of Mesothelioma, 2015-2019 (In Thousands)
Figure 119: Asia Pacific Gene Therapy Market - By Vector Type, By Value, 2015-2025 (USD Million)
Figure 120: Asia Pacific Gene Therapy Market - By Application, By Value, 2015-2025 (USD Million)
Figure 121: Market Opportunity Chart of Asia Pacific Gene Therapy Market - By Country, By Value, 2025
Figure 122: Asia Pacific Gene Therapy Market, By Country, 2019, 2025
Figure 123: China Gene Therapy Market Size, By Value, 2015-2025 (USD Million)
Figure 124: China Prevalence of Neurological Disorders, 2015-2019 (In Billions)
Figure 125: China Prevalence of Cardiovascular Diseases, 2015-2019 (In Millions)
Figure 126: China Prevalence of Total Cancer, 2015-2019 (In Millions)
Figure 127: China Prevalence of Schizophrenia, 2015-2019 (In Millions)
Figure 128: China Prevalence of Alzheimer's Disease and Other Dementias, 2015-2019 (In Millions)
Figure 129: China Prevalence of Sickle Cell Disorders, 2015-2019 (In Millions)
Figure 130: China Prevalence of Mesothelioma, 2015-2019 (In Thousands)
Figure 131: China Gene Therapy Market - By Vector Type, By Value, 2015-2025 (USD Million)
Figure 132: China Gene Therapy Market - By Application, By Value, 2015-2025 (USD Million)
Figure 133: Japan Gene Therapy Market Size, By Value, 2015-2025 (USD Million)
Figure 134: Japan Prevalence of Neurological Disorders, 2015-2019 (In Billions)
Figure 135: Japan Prevalence of Cardiovascular Diseases, 2015-2019 (In Millions)
Figure 136: Japan Prevalence of Total Cancer, 2015-2019 (In Millions)
Figure 137: Japan Prevalence of Schizophrenia, 2015-2019 (In Millions)
Figure 138: Japan Prevalence of Alzheimer's Disease and Other Dementias, 2015-2019 (In Millions)
Figure 139: Japan Prevalence of Sickle Cell Disorders, 2015-2019 (In Millions)
Figure 140: Japan Prevalence of Mesothelioma, 2015-2019 (In Thousands)
Figure 141: Japan Gene Therapy Market - By Vector Type, By Value, 2015-2025 (USD Million)
Figure 142: Japan Gene Therapy Market - By Application, By Value, 2015-2025 (USD Million)
Figure 143: India Gene Therapy Market Size, By Value, 2015-2025 (USD Million)
Figure 144: India Prevalence of Neurological Disorders, 2015-2019 (In Billions)
Figure 145: India Prevalence of Cardiovascular Diseases, 2015-2019 (In Millions)
Figure 146: India Prevalence of Total Cancer, 2015-2019 (In Millions)
Figure 147: India Prevalence of Schizophrenia, 2015-2019 (In Millions)
Figure 148: India Prevalence of Alzheimer's Disease and Other Dementias, 2015-2019 (In Millions)
Figure 149: India Prevalence of Sickle Cell Disorders, 2015-2019 (In Millions)
Figure 150: India Prevalence of Mesothelioma, 2015-2019 (In Thousands)
Figure 151: India Gene Therapy Market - By Vector Type, By Value, 2015-2025 (USD Million)
Figure 152: India Gene Therapy Market - By Application, By Value, 2015-2025 (USD Million)
Figure 153: South Korea Gene Therapy Market Size, By Value, 2015-2025 (USD Million)
Figure 154: South Korea Prevalence of Neurological Disorders, 2015-2019 (In Billions)
Figure 155: South Korea Prevalence of Cardiovascular Diseases, 2015-2019 (In Millions)
Figure 156: South Korea Prevalence of Total Cancer, 2015-2019 (In Millions)
Figure 157: South Korea Prevalence of Schizophrenia, 2015-2019 (In Millions)
Figure 158: South Korea Prevalence of Alzheimer's Disease and Other Dementias, 2015-2019 (In Millions)
Figure 159: South Korea Prevalence of Sickle Cell Disorders, 2015-2019 (In Millions)
Figure 160: South Korea Prevalence of Mesothelioma, 2015-2019 (In Thousands)
Figure 161: South Korea Gene Therapy Market - By Vector Type, By Value, 2015-2025 (USD Million)
Figure 162: South Korea Gene Therapy Market - By Application, By Value, 2015-2025 (USD Million)
Figure 163: Market Attractiveness of Global Gene Therapy Market - By Vector Type, 2025
Figure 164: Market Attractiveness of Global Gene Therapy Market - By Application, 2025
Figure 165: Market Attractiveness of Global Gene Therapy Market - By Region, 2025
Figure 166: Market Share of Leading Global Gene Therapy Companies, 2019 (In %)
Figure 167: Voyager Therapeutics Revenue, 2015-2019 (In USD Million)
Figure 168: Novartis AG Revenue, 2015-2019 (In USD Billion)
Figure 169: Novartis AG Net Revenue, By Business Segment, 2018 (In %)
Figure 170: Novartis AG Net Revenue, By Business Segment, 2019 (In %)
Figure 171: Novartis AG Net Revenue, By Geographic Segment, 2018 (In %)
Figure 172: Novartis AG Net Revenue, By Geographic Segment, 2019 (In %)
Figure 173: Roche Group Revenue, 2016-2019 (In USD Billion)
Figure 174: Roche Group Net Revenue, By Business Segment, 2018 (In %)
Figure 175: Roche Group Net Revenue, By Business Segment, 2019 (In %)
Figure 176: Roche Group Net Revenue, By Geographic Segment, 2018 (In %)
Figure 177: Roche Group Net Revenue, By Geographic Segment, 2019 (In %)
Figure 178: Orchard Therapeutics PLC Revenue, 2018-2019 (In USD Million)
Figure 179: Alnylam Pharmaceuticals Inc. Revenue, 2015-2019 (In USD Million)
Figure 180: Alnylam Pharmaceuticals Inc. Net Revenue, By Geographic Region, 2018 (In %)
Figure 181: Alnylam Pharmaceuticals Inc. Net Revenue, By Geographic Region, 2019 (In %)
Figure 182: AnGes Inc. Revenue, 2015-2019 (In USD Million)
Figure 183: Akcea Therapeutics Revenue, 2015-2019 (In USD Million)
Figure 184: BlueBird Bio Inc. Revenue, 2015-2019 (In USD Million)
Figure 185: Sarepta Therapeutics Revenue, 2015-2019 (In USD Million)

SECONDARY RESEARCH
Secondary Research Information is collected from a number of publicly available as well as paid databases. Public sources involve publications by different associations and governments, annual reports and statements of companies, white papers and research publications by recognized industry experts and renowned academia etc. Paid data sources include third party authentic industry databases.

PRIMARY RESEARCH
Once data collection is done through secondary research, primary interviews are conducted with different stakeholders across the value chain like manufacturers, distributors, ingredient/input suppliers, end customers and other key opinion leaders of the industry. Primary research is used both to validate the data points obtained from secondary research and to fill in the data gaps after secondary research.

MARKET ENGINEERING
The market engineering phase involves analyzing the data collected, market breakdown and forecasting. Macroeconomic indicators and bottom-up and top-down approaches are used to arrive at a complete set of data points that give way to valuable qualitative and quantitative insights. Each data point is verified by the process of data triangulation to validate the numbers and arrive at close estimates.

EXPERT VALIDATION
The market engineered data is verified and validated by a number of experts, both in-house and external.

REPORT WRITING/ PRESENTATION
After the data is curated by the mentioned highly sophisticated process, the analysts begin to write the report. Garnering insights from data and forecasts, insights are drawn to visualize the entire ecosystem in a single report.